

Il carcinoma mammario metastatico HR+/HER2- negativo: i nuovi algoritmi alla luce delle nuove opzioni terapeutiche



Sessione 2: CASO CLINICO

Luisa Carbognin

U.O.C. Oncologia,

Università di Verona, A.O.U.I., Verona

Negrar, 16 Aprile 2018

History & Clinical Presentation

- 53 year-old female patient
- Post-menopause
- Never smoker, BMI=22
- No family history of breast or ovarian cancer
- Comorbidities:
 - Gilbert's Syndrome
 - Atrial septal aneurysm
- March 2017: Low back pain since December 2016, uncontrolled with anti-inflammatory drugs
 - Lumbar spine and pelvic bone MRI: multiple bone lesions suspected for metastases
 - Oncologic Visit (April 24th 2017): PS ECOG: 2 (disabling pain); palpable mass in right breast; reactive depressive symptoms
 - ✓ US-mammography: single nodule in the upper-exterior quadrant of right breast (21 mm)



Diagnosis

- <u>Histology</u>:
 - Breast invasive carcinoma with solid and colloid aspects
 - Grading 3 (solid)
 - Ki67: 25%
 - ER: 90%
 - PgR: 20%
 - HER2-negative [IHC (HERcep test) score 1+]
 - Grading 2 (colloid)
 - Vascular invasion

CT scan:

- Right breast nodule
- Multiple bone metastases
- No visceral metastases

¹⁸FDG PET-CT:

- Metabolic-active area in the right breast (25 mm);

Staging


- Multifocal osteolytic bone metastases:
 - Spine, Pelvic Bone, Ribs, Femurs, Skull


cT2 cN0 M1 Stage IV (*De novo*) Luminal-like, HER2-negative disease

Baseline CT and ¹⁸FDG PET-CT


ALC: NO.


1 States of Column States and States





De Novo Stage IV in real-life





SEER 2006-2012^[1]: ~6% *De Novo* Stage IV <u>AIOM-AIRTUM 2017^[2]:</u> ~ 3,000 new *De Novo* Stage IV cases in 2017


1National Cancer Institute. SEER stat fact sheet. Accessed October 21st, 2017 2AIOM-AIRTUM: i numeri del cancro in Italia 2017

How many of these patients are represented in modern Phase III trials with new drugs?

	MONALEESA-2 (n=668)	PALOMA-2 (n=666)	SWOG-0226 (n=707)	FALCON (n=462)	MONARCH-3 (n=493)
Disease Free Interval					
De Novo MBC	34 %	36%	39%	LABC 18 %	41%
< 12 mo	2 %	22 %	nil	MBC 87 %	NR
> 12 mo	64 %	42 %	(> 10 yr) 28%		NR
Prior Treatment					
Adjuvant Endocrine Rx	52 %	56 %	40 %	nil	46%
Adjuvant Chemotherapy	37 %	48%	33 %	19 %	38%
Chemotherapy for MBC	nil	nil	nil	17 %	nil
Site of Disease					
Visceral	59 %	49 %	54 %	55 %	52%
Bone only	22 %	22 %	22 %	NR	21%
Median PFS for AI (control arm)	14.7 mo	14.5 mo	13.5 mo	13.8 mo	14.7 mo
(95 % CI)	(13.0 – 16.5)	(12.9 - 17.1)	(12.1 – 15.1)	(NR)	11.9 – 16.5

Updated - Johnston S, ESMO 2016

ABC: Treatment Goals



Multidisciplinary Strategy

Multidisciplinary discussion:

1) Pain management

- Opioid and non-steroidal anti-inflammatory analgesics
- Bone palliative Radiotherapy
- Orthopedic evaluation

2) Psychological support

- Patient & relatives
- 3) Bone stabilizing agent
 - Prevention of SREs
- 4) Oncologic systemic treatment

Treatment Tailoring in ABC

Treatment choice should consider AT LEAST these factors:

- HR and HER2 status
- Previous therapies and their toxicities
- Disease-free interval
- Tumor burden (defined as number and site of metastases)
- Biological age
- Performance status
- Comorbidities (including organ dysfunctions)
- Menopausal status (for ET)
- Need for a rapid disease/symptom control
- Patient preferences
- Socio-economic and psychological factors
- Available therapies in the patient's country

Cardoso F et al., AO 2017

LoE: Expert Opinion (Consensus: 100%)

Guidelines for Luminal ABC







 Endocrine therapy (ET) is the preferred option for luminal disease, unless there is visceral crisis or concern/proof of endocrine resistance.

All guidelines are in agreement with this recommendation

- Sequential hormone therapy is the preferential treatment.
- The preferred 1st line ET for post-menopausal patients depends on type and duration of adjuvant ET as well as time relapsed from the end of adjuvant ET; it can be an aromatase inhibitor, (tamoxifen) or fulvestrant.
- The addition of the CDK4/6 inhibitor to an aromatase inhibitor, as 1st line therapy, for post-menopausal patients represents one of the preferred treatment options.

Systemic Treatment Options

• ET

- Aromatase Inhibithor
- Fulvestrant

ET + CDK4/6 inhibitor

- Letrozole + Palbociclib (CNN)
- Clinical Trial
 - COMPLEEMENT-1 (Phase IIIb, Single Arm Trial) Letrozole + Ribociclib

A.I. vs Tamoxifene vs Fulvestrant+A.I.

PFS / TTP of Als as 1st-line endocrine therapy trials in HR+ MBC

Trial	Date	AI (months)	Tamoxifen (months)	AI + fulvestrant 250mg (months)	Hazard Ratio
Nabholtz et al Anastrozole vs tamoxifen	2000	11.1	5.6	-	0.81
Bonneterre et al Anastrozole vs tamoxifen	2001	8.2	8.3		0.99
Mouridsen et al Letrozole vs tamoxifen	2001	9.4	6.0	-	0.72
Chernozemsky et al Exemestane vs tamoxifen	2007	12.0	8.3		-
Paridaens et al Exemestane vs tamoxifen	2008	9.9	5.8	-	0.84
Mehta et al Anastrozole vs anastrozole + fulvestrant 250mg	2012	13.5		15.0	0.80
Bergh et al Anastrozole vs anastrozole + fulvestrant 250mg	2012	10.2		10.8	0.99
Range		8-13	6-8	10-15	

A.I. as comparator in recent 1st-Line Phase III Trials


	MONALEESA-2 (n=668)	PALOMA-2 (n=666)	SWOG-0226 (n=707)	FALCON (n=462)	MONARCH-3 (n=493)
Disease Free Interval					
De Novo MBC	34 %	36%	39%	LABC 18 %	41%
< 12 mo	2 %	22 %	nil	MBC 87 %	NR
> 12 mo	64 %	42 %	(> 10 yr) 28%		NR
Prior Treatment					
Adjuvant Endocrine Rx	52 %	56 %	40 %	nil	46%
Adjuvant Chemotherapy	37 %	48%	33 %	19 %	38%
Chemotherapy for MBC	nil	nil	nil	17 %	Nil
Site of Disease					
Visceral	59 %	49 %	54 %	55 %	52%
Bone only	22 %	22 %	22 %	NR	21%
Median PFS for AI (control arm)	14.7 mo	14.5 mo	13.5 mo	13.8 mo	14.7 mo
(95 % CI)	(13.0 – 16.5)	(12.9 - 17.1)	(12.1 – 15.1)	(NR)	11.9 – 16.5

Updated - Johnston S, ESMO 2016


Fulvestrant [500mg] vs A.I.

FALCON

- Randomized, double-blind, multicenter, phase 3 trial
- Postmenopausal women with inoperable locally advanced or metastatic ER-positive/HER2negative breast cancer (N = 462)
- · No prior hormone therapy
- Primary endpoint: PFS
- Secondary endpoints: OS, ORR, DOR, EDOR, CBR, DOCB, EDOCB, HRQoL, safety




Patients allowed 1 line of chemotherapy




Without Visceral Disease Proportion of Patients Alive and Progression-Free Fulvestrant 500 mg (n=95) Anastrozole 1 mg (n=113) HR 0.59 (95% CI 0.42-0.84) Median progression-free survival Fulvestrant: 22-3 months Anastrozole: 13-8 months 15 18 21 12 24 27 30 33 36 39 Time from randomisation (months) Number at risk Fulvestrant 95 84 80 72 60 57 51 44 34 23 14 4 1 0 41 Anastrozole 113 98 78 67 56 47 27 21 16 11 6 0 0





Robertson J et al., Lancet 2016

Consistency of data favouring the addition of CDK4/6 inhibitors to Als




placebo arm

et al., NEJM 2016; 3] Goetz MP et al., JCO 2017

Focus on *De Novo* ABC

PALOMA 2^[1]




Favors Abemaciclib Arm

Favors Placebo Arm

1] Finn RS et al., NEJM 2016; 2] Hortobagyi GN et al., NEJM 2016; 3] Goetz MP et al., JCO 2017

De Novo ABC in MONALEESA-2




O'Shaughnessy J et al., Breast Cancer Research and Treatment 2018

How many patients with bone only disease are represented in modern Phase III trials?


	MONALEESA-2 (n=668)	PALOMA-2 (n=666)	SWOG-0226 (n=707)	FALCON (n=462)	MONARCH-3 (n=493)
Disease Free Interval					
De Novo MBC	34 %	36%	39%	LABC 18 %	41%
< 12 mo	2 %	22 %	nil	MBC 87 %	NR
> 12 mo	64 %	42 %	(> 10 yr) 28%		NR
Prior Treatment					
Adjuvant Endocrine Rx	52 %	56 %	40 %	nil	46%
Adjuvant Chemotherapy	37 %	48%	33 %	19 %	38%
Chemotherapy for MBC	nil	nil	nil	17 %	Nil
Site of Disease					
Visceral	59 %	49 %	54 %	55 %	52%
Bone only	22 %	22 %	22 %	NR	21%
Median PFS for AI (control arm)	14.7 mo	14.5 mo	13.5 mo	13.8 mo	14.7 mo
(95 % CI)	(13.0 – 16.5)	(12.9 - 17.1)	(12.1 – 15.1)	(NR)	11.9 – 16.5

Focus on Bone only Disease



1] Finn RS et al., NEJM 2016; 2] Hortobagyi GN et al., NEJM 2016; 3] Goetz MP et al., JCO 2017

Bone only Disease PFS in MONARCH-3 & PALOMA-2



1] Goetz MP et al., JCO 2017 2] Turner NC et al., AO 2018



Summary

-	HR and HER2 status	Luminal	
-	Previous therapies and their toxicities	No pre	vious treatment
-	Disease-free interval		
_	Tumor burden (defined as number and site of	metastases) High
-	Biological age		Young
-	Performance status	Poor	due to disease)
-	Comorbidities (including organ dysfunctions)		NO
_	Menopausal status (for ET)	Р	ost-menopausa
-	Need for a rapid disease/symptom control		Synthomatic Synthomatic
-	Patient preferences	Discuss	ion the options
_	Socio-economic and psychological factors		Depression
-	Available therapies in the patient's country	New	drugs available

LoE: Expert Opinion (Consensus: 100%)

Cardoso F et al., AO 2017



- The patient started:
 - Letrozole (2.5 mg daily)
 - Ribociclib (600 mg daily d1-21, q4w)
 - Zoledronic acid (4 mg q4w) + vitamin D supplementation

Clinical Course -1

- After 1st cycle (d28):
 - G4 Neutropenia (asymptomatic)
 - G2 Nausea
 - G1 Vomiting
 - G1 Anemia
 - No bilirubin alterations
 - No EKG alterations

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Adverse Event	Ribociclib Group (N=334)		Placebo Group (N=330)†			
	Any Grade	Grade 3	Grade 4	Any Grade	Grade 3	Grade 4
			number of po	atients (percent)		
Any adverse event	329 (98.5)	221 (66.2)	50 (15.0)	320 (97.0)	105 (31.8)	3 (0.9)
Neutropenia:	248 (74.3)	166 (49.7)	32 (9.6)	17 (5.2)	3 (0.9)	0
Nausea	172 (51.5)	8 (2.4)	0	94 (28.5)	2 (0.6)	0
Infections	168 (50.3)	12 (3.6)	2 (0.6)	140 (42.4)	7 (2.1)	1 (0.3)
Fatigue	122 (36.5)	7 (2.1)	1 (0.3)	99 (30.0)	3 (0.9)	0
Diarrhea	117 (35.0)	4 (1.2)	0	73 (22.1)	3 (0.9)	0
Alopecia	111 (33.2)	NA	NA	51 (15.5)	NA	NA
Leukopenia	110 (32.9)	66 (19.8)	4 (1.2)	13 (3.9)	2 (0.6)	0
Vomiting	98 (29.3)	12 <mark>(</mark> 3.6)	0	51 (15.5)	3 (0.9)	0


Treatment exposure and dose adjustments

	Ribociclib + Letrozole n=334		Placebo + Letrozole n=330	
	Ribociclib	Letrozole	Placebo	Letrozole
Treatment exposure				
Median duration of exposure, months	12	13	12	12
Median relative dose intensity, %	88	100	100	100
Dose adjustments				
Dose interruptions, n (%)	257 (77)	132 (40)	134 (41)	107 (32)
Dose reductions due to AEs, n (%)	169 (51)	-	14 (4.2)	-

	Ribociclib + Letrozole n=334	Placebo + Letrozole n=334
Treatment ongoing, n (%)	195 (58)	154 (46)
Treatment discontinued, n (%)	139 (42)	180 (54)
Primary reason for treatment discontinuation, n (%)		
Disease progression	87 (26)	146 (44)
Adverse events	25 (7.5)	7 (2.1)
Patient decision	12 (3.6)	13 (3.9)
Physician decision	10 (3.0)	13 (3.9)
Protocol deviation	3 (0.9)	1 (0.3)
Death	2* (0.6)	0

Hortobagyi GN et al., ESMO 2016

PFS according to dose reductions in PALOMA-3



Verma S et al., The Oncologist 2016

Clinical Course -2

- <u>2nd cycle</u>: Dose delay and next lower dose of ribociclib
 - The patient reduced **Ribociclib** (400 mg daily)
- June 2017: Palliative Radiotherapy
 - 30 Gy Right femur and pelvic bone
- After 2nd and 3rd cycle:
 - No Nausea and Vomiting
 - G2 Neutropenia
 - No bilirubin alterations
 - Excellent pain control
 - PS ECOG: 0
 - Improved Health-related Quality of Life (FACT-B questionnaire)
 - Clinical evaluation \rightarrow breast nodule initial response
- July 2017: After 3 months of treatment the CT scan showed:
 - Stable disease (bone metastases and right breast nodule)

Clinical Course -3

- The patient continued Ribociclib (400 mg daily d1-21, q4w), Letrozole and Zoledronic Acid
- After 4th cycle:
 - G2 Neutropenia
 - No bilirubin alterations
 - Antalgic drugs interruption
 - PS ECOG: 0
 - Clinical evaluation \rightarrow breast nodule initial response
- <u>April 2018</u>: After 11 months of treatment the CT scan showed:
 - Stable disease (bone metastases and right breast nodule)
- The patient is still ongoing with the same treatment

Neutrophils Count



Second Line Treatment Options

- Best sequence still unknown
 - [No reliable data with regard to therapeutic benefit of subsequent treatments after CDK4/6 inhibitors after progression; only PALOMA-3 available]¹
- Options for 2nd line treatment:
 - Exemestane + Everolimus
 - Fulvestrant
 - CT?
 - Clinical Trial [ex. GIM16]:
 Exemestane+Everolimus → Fulvestrant or
 Fulvestrant → Exemestane+Everolimus

Multidisciplinary approach was crucial


Conclusion

- The combination of ET with a CDK4/6 inhibitor seems a valuable treatment option for this patient
 - -PS improvement
 - ...with a improved QoL
 - -Good safety profile
 - Disease control

Discussion

- Should the combination of a ET with CDK4/6 inhibitor be offered as the 1st-line treatment to the majority of patients with luminal ABC?
- What optimal sequential strategy to give CDK4/6 inhibitors?
 - Ongoing CDK4/6 inhibitors trials in patients who progressed on CDK4/6 inhibitors containing therapy
 - Novel agents that inhibit mechanisms of ET resistance mechanisms are in clinical trial
- To date, no clear factors to identify patients for whom ET alone is enough
- What ET is the best partner for CDK4/6?

Phase II, open-label, first-line setting



PARSIFAL Trial

ClinicalTrials.gov. NCT02491983.

Thank you for your attention

MIL